p53 abnormalities in splenic lymphoma with villous lymphocytes

Alicja M. Gruszka-Westwood, Rifat A. Hamoudi, Estella Matutes, Esperanza Tuset, Daniel Catovsky

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The incidence and role of p53 abnormalities have not been reported in splenic lymphoma with villous lymphocytes (SLVL), the leukemic counterpart of splenic marginal zone lymphoma. Because p53 abnormalities correlate with progressive and refractory disease in cancer and isochromosome 17q has been described in SLVL, a low-grade lymphoma that behaves aggressively in a minority of patients, this study investigated p53 changes by molecular and immunophenotypic methods in samples from 59 patients. The p53 deletion was analyzed by fluorescence in situ hybridization, and p53 protein expression was assessed by immunocytochemistry in 35 of 59 cases and by flow cytometry in 20 of 35 patients. Ten patients (17%) had a monoallelic p53 loss, 3 (9%) of 35 nuclear protein expression by immunocytochemistry, and 2 (10%) of 20 by flow cytometry. Two patients had both deletion and protein expression. Direct sequencing of all p53 exons was used to delineate mutations in 9 of 11 patients with an identified abnormality. Mutations, both compromising p53 DNA binding, were identified in the 2 patients with deletion and protein accumulation. Kaplan-Meier analysis revealed a significantly worse survival for patients with p53 abnormalities. Although p53 abnormalities are infrequent in SLVL, they underlie a more aggressive disease course and poor prognosis.

Original languageEnglish
Pages (from-to)3552-3558
Number of pages7
JournalBlood
Volume97
Issue number11
DOIs
Publication statusPublished - Jun 1 2001

Fingerprint

Lymphocytes
Lymphoma
Flow cytometry
Proteins
Nuclear Proteins
Refractory materials
Exons
Fluorescence
Flow Cytometry
Immunohistochemistry
DNA
Isochromosomes
Mutation
Kaplan-Meier Estimate
Fluorescence In Situ Hybridization
Non-Hodgkin's Lymphoma
Survival
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Gruszka-Westwood, A. M., Hamoudi, R. A., Matutes, E., Tuset, E., & Catovsky, D. (2001). p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood, 97(11), 3552-3558. https://doi.org/10.1182/blood.V97.11.3552

p53 abnormalities in splenic lymphoma with villous lymphocytes. / Gruszka-Westwood, Alicja M.; Hamoudi, Rifat A.; Matutes, Estella; Tuset, Esperanza; Catovsky, Daniel.

In: Blood, Vol. 97, No. 11, 01.06.2001, p. 3552-3558.

Research output: Contribution to journalArticle

Gruszka-Westwood, AM, Hamoudi, RA, Matutes, E, Tuset, E & Catovsky, D 2001, 'p53 abnormalities in splenic lymphoma with villous lymphocytes', Blood, vol. 97, no. 11, pp. 3552-3558. https://doi.org/10.1182/blood.V97.11.3552
Gruszka-Westwood, Alicja M. ; Hamoudi, Rifat A. ; Matutes, Estella ; Tuset, Esperanza ; Catovsky, Daniel. / p53 abnormalities in splenic lymphoma with villous lymphocytes. In: Blood. 2001 ; Vol. 97, No. 11. pp. 3552-3558.
@article{dc2ecfbcca6149a1a37e6bef36ac2335,
title = "p53 abnormalities in splenic lymphoma with villous lymphocytes",
abstract = "The incidence and role of p53 abnormalities have not been reported in splenic lymphoma with villous lymphocytes (SLVL), the leukemic counterpart of splenic marginal zone lymphoma. Because p53 abnormalities correlate with progressive and refractory disease in cancer and isochromosome 17q has been described in SLVL, a low-grade lymphoma that behaves aggressively in a minority of patients, this study investigated p53 changes by molecular and immunophenotypic methods in samples from 59 patients. The p53 deletion was analyzed by fluorescence in situ hybridization, and p53 protein expression was assessed by immunocytochemistry in 35 of 59 cases and by flow cytometry in 20 of 35 patients. Ten patients (17{\%}) had a monoallelic p53 loss, 3 (9{\%}) of 35 nuclear protein expression by immunocytochemistry, and 2 (10{\%}) of 20 by flow cytometry. Two patients had both deletion and protein expression. Direct sequencing of all p53 exons was used to delineate mutations in 9 of 11 patients with an identified abnormality. Mutations, both compromising p53 DNA binding, were identified in the 2 patients with deletion and protein accumulation. Kaplan-Meier analysis revealed a significantly worse survival for patients with p53 abnormalities. Although p53 abnormalities are infrequent in SLVL, they underlie a more aggressive disease course and poor prognosis.",
author = "Gruszka-Westwood, {Alicja M.} and Hamoudi, {Rifat A.} and Estella Matutes and Esperanza Tuset and Daniel Catovsky",
year = "2001",
month = "6",
day = "1",
doi = "10.1182/blood.V97.11.3552",
language = "English",
volume = "97",
pages = "3552--3558",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - p53 abnormalities in splenic lymphoma with villous lymphocytes

AU - Gruszka-Westwood, Alicja M.

AU - Hamoudi, Rifat A.

AU - Matutes, Estella

AU - Tuset, Esperanza

AU - Catovsky, Daniel

PY - 2001/6/1

Y1 - 2001/6/1

N2 - The incidence and role of p53 abnormalities have not been reported in splenic lymphoma with villous lymphocytes (SLVL), the leukemic counterpart of splenic marginal zone lymphoma. Because p53 abnormalities correlate with progressive and refractory disease in cancer and isochromosome 17q has been described in SLVL, a low-grade lymphoma that behaves aggressively in a minority of patients, this study investigated p53 changes by molecular and immunophenotypic methods in samples from 59 patients. The p53 deletion was analyzed by fluorescence in situ hybridization, and p53 protein expression was assessed by immunocytochemistry in 35 of 59 cases and by flow cytometry in 20 of 35 patients. Ten patients (17%) had a monoallelic p53 loss, 3 (9%) of 35 nuclear protein expression by immunocytochemistry, and 2 (10%) of 20 by flow cytometry. Two patients had both deletion and protein expression. Direct sequencing of all p53 exons was used to delineate mutations in 9 of 11 patients with an identified abnormality. Mutations, both compromising p53 DNA binding, were identified in the 2 patients with deletion and protein accumulation. Kaplan-Meier analysis revealed a significantly worse survival for patients with p53 abnormalities. Although p53 abnormalities are infrequent in SLVL, they underlie a more aggressive disease course and poor prognosis.

AB - The incidence and role of p53 abnormalities have not been reported in splenic lymphoma with villous lymphocytes (SLVL), the leukemic counterpart of splenic marginal zone lymphoma. Because p53 abnormalities correlate with progressive and refractory disease in cancer and isochromosome 17q has been described in SLVL, a low-grade lymphoma that behaves aggressively in a minority of patients, this study investigated p53 changes by molecular and immunophenotypic methods in samples from 59 patients. The p53 deletion was analyzed by fluorescence in situ hybridization, and p53 protein expression was assessed by immunocytochemistry in 35 of 59 cases and by flow cytometry in 20 of 35 patients. Ten patients (17%) had a monoallelic p53 loss, 3 (9%) of 35 nuclear protein expression by immunocytochemistry, and 2 (10%) of 20 by flow cytometry. Two patients had both deletion and protein expression. Direct sequencing of all p53 exons was used to delineate mutations in 9 of 11 patients with an identified abnormality. Mutations, both compromising p53 DNA binding, were identified in the 2 patients with deletion and protein accumulation. Kaplan-Meier analysis revealed a significantly worse survival for patients with p53 abnormalities. Although p53 abnormalities are infrequent in SLVL, they underlie a more aggressive disease course and poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0035383803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035383803&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.11.3552

DO - 10.1182/blood.V97.11.3552

M3 - Article

VL - 97

SP - 3552

EP - 3558

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -